Evidence map›Paper›PMID 36591449›Full record

ArticleFrontiers in oncology2022

Low-dose computed tomography for lung cancer screening in Anhui, China: A randomized controlled trial.

Feng Rong, Rui Shi, Lili Hu, Ran Chen, Daoyue Wang, Xiazhi Lv, Yong Zhao, Wei Huang, Yang Yang, Hongyang Zhou and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Feng RongCancer Centre, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui, China.
Rui ShiCancer Centre, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui, China.
Lili HuCancer Centre, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui, China.
Ran ChenCancer Centre, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui, China.
Daoyue WangCancer Centre, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui, China.
Xiazhi LvCancer Centre, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui, China.
Yong ZhaoCancer Centre, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui, China.
Wei HuangCancer Centre, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui, China.
Yang YangCancer Centre, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui, China.
Hongyang ZhouCancer Centre, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui, China.
Kaige HongCancer Centre, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui, China.
Lu'an First People's Hospital · CNAnhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung cancer is the leading cause of cancer-related death worldwide, with risk factors such as age and smoking. Low-dose computed tomography screening can reduce lung cancer mortality. However, its effectiveness in Asian populations remains unclear. Most Asian women with lung cancer are non-smokers who have not been screened. We conducted a randomized controlled trial to evaluate the performance of low-dose computed tomography screening in a Chinese population, including high-risk smokers and non-smokers exposed to passive smoking. The baseline data are reported in this study. Methods: Between May and December 2019, eligible participants were randomized in a ratio of 1:1:1 to a screening (two arms) or control cohort. Non-calcified nodules/masses with a diameter >4 mm on low-dose computed tomography were considered positive findings. Results: In total, 600 patients (mean age, 59.1 ± 6.9 years) underwent low-dose computed tomography. Women accounted for 31.5% (189/600) of patients; 89.9% (170/189) were non-smokers/passive smokers. At baseline, the incidence of lung cancer was 1.8% (11/600). The incidence of lung cancer was significantly lower in smokers than in female non-smokers/passive smokers (1.0% [4/415] Conclusions: We demonstrate the importance of including active smokers and female non-smokers/passive smokers in lung cancer screening programs. Further studies are needed to explore the risk factors, and long-term cost-benefit of screening Asian non-smoking women. Clinical trial registration: http://chictr.org.cn/showproj.aspx?proj=39003, identifier ChiCTR1900023197.

Indexed as

female lung cancerlow-dose computed tomographylung cancer screeningpassive smokingrandomized controlled trial

Identifiers

PMID36591449
PMCPMC9795014
OpenAlexW4311364178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.